Literature DB >> 1532136

IgE in Reed-Sternberg cells of Hodgkin's disease with eosinophilia.

M Samoszuk1.   

Abstract

Tissues containing Hodgkin's disease (HD) are frequently infiltrated by large numbers of eosinophils. Because eosinophils as well as Reed-Sternberg (RS) cells express membrane receptors (CD23) for IgE, this study was performed to determine if IgE is present in tissue sections of HD and to correlate the results, when possible, with serum IgE levels and the presence of interleukin-5 (IL-5) messenger RNA (mRNA) in RS cells. Paraffin-embedded, B-5-fixed slices of 13 cases of HD, one case of acquired immunodeficiency syndrome (AIDS)-related HD, seven cases of benign lymphoid hyperplasia (including two cases from HD patients), and five cases of B-cell lymphomas were analyzed by a sensitive immunoperoxidase staining technique that used a murine monoclonal antibody specific for human IgE. In the benign hyperplastic lymph nodes and non-Hodgkin's lymphomas, IgE was generally detectable only in rare plasma cells and in follicular dendritic cells. In 11 of the 14 cases of HD, including one case of AIDS-related HD, IgE was readily detectable within RS cells and variants and on the surrounding cells and connective tissue. These cases also had significant numbers of eosinophils, and IL-5 mRNA was detectable in three of the cases that were tested. Serum IgE was moderately elevated in the two serum specimens from HD patients that were available for analysis. The results of this study, therefore, indicate that some cases of HD contain abundant deposits of IgE, which may account for the extensive infiltration by eosinophils seen in this neoplasm.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532136

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Relation of follicular dendritic reticulum cells to Reed-Sternberg cells of Hodgkin's disease with emphasis on the expression of CD21 antigen.

Authors:  G Delsol; F Meggetto; P Brousset; E Cohen-Knafo; T al Saati; P Rochaix; B Gorguet; B Rubin; J J Voigt; S Chittal
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

2.  Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.

Authors:  Lynn I Levin; Elizabeth C Breen; Brenda M Birmann; Julie L Batista; Larry I Magpantay; Yuanzhang Li; Richard F Ambinder; Nancy E Mueller; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-03-24       Impact factor: 4.254

Review 3.  Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.

Authors:  D R Lucey; M Clerici; G M Shearer
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

4.  EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines.

Authors:  Shu-Chun Tsai; Sue-Jane Lin; Po-Wen Chen; Wen-Yi Luo; Te-Huei Yeh; Hsei-Wei Wang; Chi-Ju Chen; Ching-Hwa Tsai
Journal:  Blood       Date:  2009-05-05       Impact factor: 22.113

5.  Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells.

Authors:  U Kapp; W C Yeh; B Patterson; A J Elia; D Kägi; A Ho; A Hessel; M Tipsword; A Williams; C Mirtsos; A Itie; M Moyle; T W Mak
Journal:  J Exp Med       Date:  1999-06-21       Impact factor: 14.307

6.  Quantitative Analysis of Tumor-associated Tissue Eosinophilia in Recurring Bladder Cancer.

Authors:  Hristo Popov; Ivan S Donev; Peter Ghenev
Journal:  Cureus       Date:  2018-09-10

7.  Hodgkin's lymphoma presenting with markedly elevated IgE: a case report.

Authors:  Anne K Ellis; Susan Waserman
Journal:  Allergy Asthma Clin Immunol       Date:  2009-12-07       Impact factor: 3.406

8.  Fecal microbiota diversity in survivors of adolescent/young adult Hodgkin lymphoma: a study of twins.

Authors:  W Cozen; G Yu; M H Gail; V K Ridaura; B N Nathwani; A E Hwang; A S Hamilton; T M Mack; J I Gordon; J J Goedert
Journal:  Br J Cancer       Date:  2013-02-26       Impact factor: 9.075

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.